Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib

References

• CasaliPGBlayJYSoft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5198203
   PubMed Web of Science ®Google Scholar
• PenelNBuiBNBayJOPhase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX StudyJ Clin Oncol2008265269527418809609
   PubMed Web of Science ®Google Scholar
• Le CesneABlayJYJudsonIPhase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trialJ Clin Oncol2005357658415659504
   PubMed Web of Science ®Google Scholar
• MakiRGWathenJKPatelSRRandomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]J Clin Oncol2007252755276317602081
   PubMed Web of Science ®Google Scholar
• García-Del-MuroXLópez-PousaAMaurelJRandomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas studyJ Clin Oncol2011292528253321606430
   PubMed Web of Science ®Google Scholar
• YoonSSSegalNHOlshenABBrennanMFSingerSCirculating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcomaAnn Oncol2004151261126615277268
   PubMed Web of Science ®Google Scholar
• RutkowskiPKaminskaJKowalskaMRukaWSteffenJCytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosisInt J Cancer Suppl2002100463471
   Google Scholar
• GraevenUAndreNAchillesEZornigCSchmiegelWSerum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcomaJ Cancer Res Clin Oncol199912557758110473871
   PubMed Web of Science ®Google Scholar
• HayesAJMostyn-JonesAKobanMUA’HernRBurtonPThomasJMSerum vascular endothelial growth factor as a tumour marker in soft tissue sarcomaBr J Surg20049124224714760675
   PubMed Web of Science ®Google Scholar
• YoonSSSegalNHParkPJAngiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expressionJ Surg Res200613528229016603191
   PubMed Web of Science ®Google Scholar
• BetsholtzCInsight into the physiological functions of PDGF through genetic studies in miceCytokine Growth Factor Rev20041521522815207813
   PubMed Web of Science ®Google Scholar
• FerraraNVEGF as a therapeutic target in cancerOncology200569Suppl 3111616301831
   PubMed Web of Science ®Google Scholar
• BergersGSongSMeyer-MorseNBergslandEHanahanDBenefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJ Clin Investig20031111287129512727920
   PubMed Web of Science ®Google Scholar
• ErberRThurnherAKatsenADCombined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanismsFASEB J20041833834014657001
   PubMed Web of Science ®Google Scholar
• GeorgeSMerriamPMakiRGMulticenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomasJ Clin Oncol2009273154316019451429
   PubMed Web of Science ®Google Scholar
• MakiRGD’AdamoDRKeohanMLPhase II study of sorafenib in patients with metastatic or recurrent sarcomasJ Clin Oncol2009273133314019451436
   PubMed Web of Science ®Google Scholar
• FoxEAplencRBagatellRA phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumorsJ Clin Oncol2010285174518121060028
   PubMed Web of Science ®Google Scholar
• SchwartzGKMakiRGRatainMJBrivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): biomarker and subset results of a phase II randomized discontinuation trialJ Clin Oncol201129SupplAbstr 10000
   Web of Science ®Google Scholar
• HarrisPABoloorACheungMDiscovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl] amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitorJ Med Chem2008514632464018620382
   PubMed Web of Science ®Google Scholar
• BukowskiRMPazopanib: a multikinase inhibitor with activity in advanced renal cell carcinomaExpert Rev Anticancer Ther20101063564520469994
   PubMed Web of Science ®Google Scholar
• KumarRKnickVBRudolphSKPharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMol Cancer Ther200762012202117620431
   PubMed Web of Science ®Google Scholar
• HurwitzHIDowlatiASainiSPhase I trial of pazopanib in patients with advanced cancerClin Cancer Res2009154220422719509175
   PubMed Web of Science ®Google Scholar
• KeisnerSVShahSRPazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinomaDrugs20117144345421395357
   PubMed Web of Science ®Google Scholar
• SleijferSRay-CoquardIPapaiZPazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)J Clin Oncol2009273126313219451427
   PubMed Web of Science ®Google Scholar
• van der GraafWTBlayJYChawlaSPPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet20123791879188622595799
   PubMed Web of Science ®Google Scholar
• Pàez-RibesMAllenEHudockJAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisCancer Cell20091522023119249680
   PubMed Web of Science ®Google Scholar
• MackeyJRKerbelRSGelmonKAControlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trialsCancer Treat Rev20123867368822365657
   PubMed Web of Science ®Google Scholar
• JonesRLFisherCAl-MuderisOJudsonIRDifferential sensitivity of liposarcoma subtypes to chemotherapyEur J Cancer2005412853286016289617
   PubMed Web of Science ®Google Scholar
• BroxtermanHJGotinkKJVerheulHMUnderstanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinibDrug Resist Updat20091211412619648052
   PubMed Web of Science ®Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer2008859260318650835
   PubMed Web of Science ®Google Scholar
• RelfMLeJeuneSScottPAExpression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesisCancer Res1997579639699041202
   PubMed Web of Science ®Google Scholar
• FernandoNTKochMRothrockCTumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factorsClin Cancer Res2008141529153918316578
   PubMed Web of Science ®Google Scholar
• BatchelorTTSorensenAGdi TomasoEAZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsCancer Cell200711839517222792
   PubMed Web of Science ®Google Scholar
• BocciGManSGreenSKIncreased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodiesCancer Res2004646616662515374976
   PubMed Web of Science ®Google Scholar
• EbosJMLeeCRChristensenJGMutsaersAJKerbelRSMultiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyProc Natl Acad Sci U S A2007104170691707417942672
   PubMed Web of Science ®Google Scholar
• EllisLMHicklinDJPathways mediating resistance to vascular endothelial growth factor-targeted therapyClin Cancer Res2008146371637518927275
   PubMed Web of Science ®Google Scholar
• ThurstonGNoguera-TroiseIYancopoulosGDThe Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growthNat Rev Cancer2007732733117457300
   PubMed Web of Science ®Google Scholar
• AugustinHGKohGYThurstonGAlitaloKControl of vascular morphogenesis and homeostasis through the angiopoietin-Tie systemNat Rev Mol Cell Biol20091016517719234476
   PubMed Web of Science ®Google Scholar
• DuRLuKVPetritschCLiuPHIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasionCancer Cell20081320622018328425
   PubMed Web of Science ®Google Scholar
• AsaharaTMuroharaTSullivanAIsolation of putative progenitor endothelial cells for angiogenesisScience19972759649679020076
   PubMed Web of Science ®Google Scholar
• PollardJWTumour-educated macrophages promote tumour progression and metastasisNat Rev Cancer20044717814708027
   PubMed Web of Science ®Google Scholar
• OrlidgeAD’AmorePAInhibition of capillary endothelial cell growth by pericytes and smooth muscle cellsJ Cell Biol1987105145514623654761
   PubMed Web of Science ®Google Scholar
• XianXHåkanssonJStåhlbergAPericytes limit tumor cell metastasisJ Clin Investig200611664265116470244
   PubMed Web of Science ®Google Scholar
• EllisLMHicklinDJVEGF-targeted therapy: mechanisms of anti-tumour activityNat Rev Cancer2008857959118596824
   PubMed Web of Science ®Google Scholar
• GotinkKJRudekMABroxtermanHJThe antiangiogenic tyrosine kinase inhibitor sunitinib has direct antitumor activity on renal and colorectal cancer cells in vitro at intratumoral concentrations achieved in miceAbstract 150 presented at the 100th Annual Meeting of the American Association of Cancer ResearchDenver, COApril 18–22, 2009
   Google Scholar
• O’ConnorRClynesMDowlingPO’DonovanNO’DriscollLDrug resistance in cancer – searching for mechanisms, markers and therapeutic agentsExpert Opin Drug Metab Toxicol2007380581718028026
   PubMed Web of Science ®Google Scholar